Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy Individuals (NCT07493850) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy Individuals
India60 participantsStarted 2026-02-27
Plain-language summary
The goal of this clinical study is to evaluate the efficacy and tolerability of EMC-CAP-2025A, an eggshell membrane-based dietary supplement, on age-related skin parameters in healthy adults.
The main questions this study aims to answer are:
* Does daily supplementation with EMC-CAP-2025A improve facial wrinkles compared to placebo?
* Does EMC-CAP-2025A improve skin hydration, firmness, elasticity, texture, and overall skin quality?
* Is EMC-CAP-2025A well tolerated when taken daily for 60 days?
Researchers will compare EMC-CAP-2025A to a placebo to assess its effects on multiple skin parameters using objective instrumental assessments and participant self-evaluations.
Participants will:
* Be randomly assigned to receive either EMC-CAP-2025A or a placebo
* Take one capsule orally once daily for 60 days
* Attend scheduled study visits at baseline, Day 30, and Day 60 for instrumental skin assessments and safety evaluations
* Complete self-assessment questionnaires related to skin quality and product tolerability
Who can participate
Age range
30 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Individuals who are willing to understand and sign a written informed consent form prior to the study.
. Healthy male and female individuals aged between 30 to 55 years (both values included).
. Individuals showing symptoms of aging, with mild to moderate wrinkles in crow's feet area based on PI discretion.
. Individuals with any one of the following skin conditions along with mild to moderate wrinkles:
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To assess the effect of Investigational product at Day 60 in comparison to baseline and placebo on Wrinkles in the nasolabial and lateral canthal region near the eyes (crow's feet)
. Individuals willing to maintain stable dietary patterns and maintain adequate hydration every day throughout the study
Exclusion criteria
. Individuals having an allergy to any of the components of the IP.
. Use of another investigational product within 90 days prior to the screening visit.
. Individuals with any dermatologic disorders or skin conditions that could interfere with the evaluation of proprietary supplement's effects.
. Individuals having an underlying disease or surgical or medical condition that could put them at risk in the opinion of Principal Investigator, including anyuncontrolled chronic or serious disease that would prevent participation in the study, such as cancer, AIDS, diabetes, obesity, renal impairment, psychiatricdisorder, compromised immunity, etc.
. Individuals having a history of self-reported allergies to cosmetic and/or sunscreen products.
. Individuals who have used or are unwilling to abstain from using any topical or systemic skin-treatment products or dietary supplements with claims toimprove skin hydration, firmness, anti-aging, anti-wrinkle, skin lightening, or dyschromia correction - including those containing alpha/beta/poly-hydroxyacids, salicylic acid, vitamin C, collagen, hyaluronic acid, soy, CoQ-10, chondroitin sulfate, hydroquinone, corticosteroids, tretinoin, retinoids, or anycombination thereof - within 1 month prior to screening or during the study period.
. Individuals currently using oral or topical health foods, supplements, pharmaceuticals, or cosmetics that claim whitening or skin-texture improvementeffects such as but not limited to glutathione, cysteine, placenta-based extracts, Vitamins C/E/A (retinol), astaxanthin, lycopene, etc., and who cannotrefrain from using them during the study period.
. Individuals who have undergone any facial cosmetic or aesthetic procedures, including beauty injections, deep or superficial-to-mid chemical peels,dermabrasion, laser resurfacing, Thermage, tanning, cosmetic surgery, or any equivalent high-energy or anti-aging facial treatments, within 3 months priorto the screening visit.